Fig. 4: PFS by C4D15 ctDNA MRD status. | Nature Cancer

Fig. 4: PFS by C4D15 ctDNA MRD status.

From: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Fig. 4

Data are presented as Kaplan–Meier curves, with tick marks indicating patients with censored data (n = 63 ctDNA-evaluable patients; n = 20 with cleared MRD at C4D15, n = 43 with detected MRD at C4D15). Median values with 95% CIs are presented alongside the respective curves. The HR for PFS in patients with MRD cleared versus MRD detected was calculated by univariate Cox regression.

Source data

Back to article page